Latest & greatest articles for doxazosin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on doxazosin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on doxazosin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for doxazosin

1. Doxazosin and Ramipril in Hypertension

Doxazosin and Ramipril in Hypertension Doxazosin and Ramipril in Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Doxazosin and Ramipril in Hypertension (DoRa) The safety and scientific validity (...) -blind parallel group study in patients with mild-to-moderate hypertension to evaluate the effects beyond the blood pressure lowering effect of treatment for 12 weeks with ramipril or doxazosin on hemostatic mechanisms and on endothelial function. Condition or disease Intervention/treatment Phase Hypertension Drug: Ramipril Drug: Doxazosin Phase 4 Detailed Description: This study aims to answer the following questions: 1) Does antihypertensive therapy with doxazosin exhibit antithrombotic effects

2016 Clinical Trials

2. [Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension]. (Abstract)

[Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension]. 26948046 2017 08 08 2018 12 02 1578-8865 42 7 2016 10 Semergen Semergen [Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension]. e108-e109 S1138-3593(16)00049-6 10.1016/j.semerg.2016.01.017 Divisón Garrote J A JA Atención Primaria, Centro de Salud Casas Ibáñez, Casas-Ibáñez, Albacete, España (...) ; Universidad Católica San Antonio de Murcia, Murcia, España. Electronic address: jadivison@telefonica.net. Escobar Cervantes C C Servicio de Cardiología, Hospital La Paz, Madrid, España. spa Journal Article Comment Espironolactona versus placebo, bisoprolol y doxazosina para determinar el tratamiento óptimo de hipertensión resistente a fármacos. 2016 03 03 Spain Semergen 9610769 1138-3593 0 Antihypertensive Agents 27O7W4T232 Spironolactone NW1291F1W8 Doxazosin Y41JS2NL6U Bisoprolol IM Lancet. 2015 Nov

2017 Semergen Controlled trial quality: uncertain

3. The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients

The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02563405 Recruitment Status : Unknown Verified

2015 Clinical Trials

4. A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD

A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2017 Clinical Trials

5. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. (Abstract)

Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. Hypertension and hypercholesterolemia are 2 major risk factors for atherosclerotic coronary artery disease (CAD). Elevations of both blood pressure and serum cholesterol levels should be reduced to control CAD risk. Doxazosin is a once-daily, long-acting, selective alpha 1-adrenergic inhibitor that is effective for the treatment of essential hypertension. During controlled studies (...) of doxazosin's antihypertensive efficacy, 3 serum lipid parameters were measured; total cholesterol, total triglyceride and high density lipoprotein (HDL) cholesterol. In 10- to 12-week placebo-controlled studies, 142 doxazosin-treated patients were compared with 155 placebo-controlled subjects. Doxazosin patients had an increase of 8.9% in the HDL/total cholesterol ratio (p less than 0.05), whereas total cholesterol, HDL cholesterol and triglyceride levels were not significantly different between the 2

1987 The American journal of cardiology

6. Is there any evidence that doxazosin causes heart failure?

Is there any evidence that doxazosin causes heart failure? Is there any evidence that doxazosin causes heart failure? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) , educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence that doxazosin causes heart failure? Much of the information we found on this question refers to the ALLHAT trial. Below we have highlighted the evidence from several sources. Clinical Evidence (1) has a section on Primary prevention: hypertension, ‘Antihypertensive

2006 TRIP Answers

7. Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans. Full Text available with Trip Pro

Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans. Posttraumatic stress disorder (PTSD) and alcohol use disorders (AUD) are two of the most common mental health disorders affecting civilians as well as military populations. If left untreated, individuals with co-occurring PTSD/AUD are at increased risk for developing other mental health problems (e.g., depression, anxiety), physical health (...) problems, reduced resiliency and military readiness, and vocational and social impairment. Substantial gaps in the treatment of co-occurring PTSD/AUD exist and there is a critical need to develop more effective pharmacological treatments. The current study addresses this gap in the literature by testing the efficacy and safety of doxazosin, a long-acting and selective alpha-1 adrenergic antagonist, as compared to placebo in reducing PTSD and AUD severity among U.S. military veterans. Noradrenergic

2018 Contemporary clinical trials Controlled trial quality: predicted high

8. ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk. (Abstract)

ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk. 26882301 2016 06 14 2018 12 02 1539-3704 164 4 2016 Feb 16 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk. JC16 10.7326/ACPJC-2016-164-4-016 Rosenberg Mark M Stephens Elizabeth E eng Journal Article Comment United States Ann Intern (...) Med 0372351 0003-4819 0 Adrenergic alpha-1 Receptor Antagonists 0 Adrenergic beta-1 Receptor Antagonists 0 Mineralocorticoid Receptor Antagonists 27O7W4T232 Spironolactone NW1291F1W8 Doxazosin Y41JS2NL6U Bisoprolol AIM IM Lancet. 2015 Nov 21;386(10008):2059-68 26414968 Adrenergic alpha-1 Receptor Antagonists therapeutic use Adrenergic beta-1 Receptor Antagonists therapeutic use Bisoprolol therapeutic use Doxazosin therapeutic use Female Humans Hypertension drug therapy Male Mineralocorticoid

2016 Annals of Internal Medicine Controlled trial quality: uncertain

9. Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. (Abstract)

Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. Given the favorable impact of α1-blockers on lipid and glucose metabolism, this study was designed to compare the efficacy of two extended-release α1-blockers (bunazosin and doxazosin) as an add-on treatment in subjects with stage 1 or 2 essential hypertension which (...) was inadequately controlled by valsartan 80 mg/day.After a 5-week treatment of valsartan monotherapy, subjects with inadequately controlled hypertension were randomized to receive either extended-release bunazosin (n = 47) or doxazosin (n = 46) after breakfast for 8 weeks. Office sitting blood pressure (BP), 24-hour ambulatory BP, and metabolic profiles were measured at baseline, start of study drug, and study end.In the intention-to-treat population (n = 93), the average daily doses of bunazosin

2016 Zhonghua Minguo xin zang xue hui za zhi = Acta Cardiologica Sinica Controlled trial quality: uncertain

10. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension. (Abstract)

Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension. The efficacy and safety of doxazosin (mean dosage 6.9 mg, range 1 to 16) in the treatment of essential hypertension were compared in a double-blind study with those of hydrochlorothiazide (HCTZ) (mean dosage, 84.6 mg, range 25 to 100) in 104 hypertensive patients treated once daily for 6 months. Thirty-five patients were also assessed for comparative effects of the 2 agents (...) on serum lipid parameters. Doxazosin produced potentially favorable changes from baseline in the concentrations of serum lipid fractions (total triglycerides, total cholesterol, high density lipoprotein [HDL] cholesterol and the derived HDL/total cholesterol ratio) compared with HCTZ. The decreases in total triglyceride and total cholesterol concentrations and an increase in the HDL/total cholesterol ratio were significantly different (p less than 0.006) from the opposite changes observed with HCTZ

1987 The American journal of cardiology

11. Doxazosin for PTSD and Alcohol Use Disorder

Doxazosin for PTSD and Alcohol Use Disorder Doxazosin for PTSD and Alcohol Use Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Doxazosin for PTSD and Alcohol Use Disorder The safety and scientific (...) Center Information provided by (Responsible Party): Medical University of South Carolina Study Details Study Description Go to Brief Summary: The study will test the efficacy of doxazosin, a long-acting and selective alpha-1 adrenergic antagonist, as compared to placebo in reducing PTSD symptomatology and alcohol use severity. Condition or disease Intervention/treatment Phase PTSD Alcohol Use Disorder Drug: Doxazosin Drug: Placebo Phase 1 Phase 2 Detailed Description: As a result of sustained

2015 Clinical Trials

12. How should conversion between doxazosin formulations be carried out in patients with hypertension?

How should conversion between doxazosin formulations be carried out in patients with hypertension? Switching from modified release doxazosin to standard release doxazosin in patients with hypertension – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Menu · · Published 15th June 2018, updated 15th January 2019 · London Medicines Information Service In 2017, NHS England published a document advising prescribers to switch doxazosin XL to standard release (...) doxazosin. This is because doxazosin XL has a significantly higher cost and relevant clinical guidelines do not identify any benefits of using it above standard release doxazosin. There are no recommendations from manufacturers or any published data available to suggest how to switch from doxazosin XL to standard release doxazosin. Therefore, in the absence of any firm recommendations, we suggest possible strategies to conduct this switch. Upon discontinuation of modified release doxazosin, the dose

2016 Specialist Pharmacy Services

13. A multicenter study of doxazosin in the treatment of essential hypertension in France. (Abstract)

A multicenter study of doxazosin in the treatment of essential hypertension in France. This study was designed to assess the efficacy and tolerance of doxazosin in patients with mild, moderate, or severe essential hypertension in a general practice setting. Ninety-six adults of a mean age of 55 1/2 years took part in the 14-week study, consisting of a placebo phase (2 weeks), a dose-adjustment phase with doxazosin (8 weeks), and a maintenance phase (4 weeks). Doxazosin, at a final mean daily (...) dose of 3.4 mg, produced a significant (p less than 0.05) reduction in blood pressure at all points of measurement during the study. The mean change in sitting blood pressure at the end of treatment was -15.4/-15.8 mm Hg. Of the 85 patients who could be categorized as a success or failure, 78 (92%) were considered a therapeutic success; 78 (89%) of the 88 efficacy-evaluable patients demonstrated an improvement in the severity category of their hypertension. Treatment with doxazosin produced

1991 American heart journal

14. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. (Abstract)

Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors. It has been suggested that adverse effects on lipids of traditional diuretic or beta-blocker regimens may diminish the potential benefits of antihypertensive therapy. Patients with mild to moderate systemic (...) hypertension and normal serum lipids (n = 191) were randomly assigned to doxazosin or atenolol. After dose titration to goal diastolic blood pressure of < or = 90 mm Hg, patients continued treatment for a further 24 weeks. The principal outcome measurement was overall coronary artery disease risk using the Framingham formula. Relative risk of coronary artery disease was reduced to 92.4% of baseline (p = 0.144) for evaluable patients taking atenolol (n = 71), and to 74.6% (p = 0.0001) for patients taking

1993 The American journal of cardiology Controlled trial quality: uncertain

15. Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. (Abstract)

Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI (...) ), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension.This trial had a prospective, open-label, blinded-evaluation design and a duration of 9 months. Patients whose blood pressure (BP) was uncontrolled (systolic BP > or = 130 mm Hg and/or diastolic BP > or = 80 mm Hg) despite at least 1 month of treatment with a renin-angiotensin blocker and diuretic were randomly allocated to receive doxazosin GITS 4 mg or atenolol 50 mg

2008 Clinical therapeutics Controlled trial quality: uncertain

16. Does doxazosin MR give better BP control over plain doxazosin? Can the MR version be switched to plain?

Does doxazosin MR give better BP control over plain doxazosin? Can the MR version be switched to plain? Does doxazosin MR give better BP control over plain doxazosin? Can the MR version be switched to plain? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document (...) across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Does doxazosin MR give better BP control over plain doxazosin? Can the MR version be switched to plain? ATTRACT found two similar questions published recently by the National Electronic Library

2010 TRIP Answers

17. Is it ok to use plain rather MR Doxazosin 4mg or 8mg when treating hypertension?

Is it ok to use plain rather MR Doxazosin 4mg or 8mg when treating hypertension? Is it ok to use plain rather MR Doxazosin 4mg or 8mg when treating hypertension? - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing (...) including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is it ok to use plain rather MR Doxazosin 4mg or 8mg when treating hypertension? The NLH Q&A Service cannot answer whether it is ok to use plain rather than MR doxazosin, as this is a clinical decision. However, we have been able

2006 TRIP Answers

18. Pharmacogenetics of Dopamine β-Hydroxylase in cocaine dependence therapy with doxazosin. Full Text available with Trip Pro

Pharmacogenetics of Dopamine β-Hydroxylase in cocaine dependence therapy with doxazosin. The α1 -adrenergic antagonist, doxazosin, has improved cocaine use disorder (CUD) presumably by blocking norepinephrine (NE) stimulation and reward from cocaine-induced NE increases. If the NE levels for release were lower, then doxazosin might more readily block this NE stimulation and be more effective. The NE available for release can be lower through a genetic polymorphism in dopamine β-hydroxylase (...) (DBH) (C-1021T, rs1611115), which reduces DβH's conversion of dopamine to NE. We hypothesize that doxazosin would be more effective in CUD patients who have these genetically lower DβH levels. This 12-week, double-blind, randomized, placebo-controlled trial included 76 CUD patients: 49 with higher DβH levels from the DBH CC genotype and 27 with lower DβH levels from T-allele carriers (CT or TT). Patients were randomized to doxazosin (8 mg/day, N = 47) or placebo (N = 29) and followed with thrice

2018 Addiction biology Controlled trial quality: predicted high

19. Doxazosin in the treatment of benign prostatic hyperplasia. A review of the safety profile in older patients. Full Text available with Trip Pro

Doxazosin in the treatment of benign prostatic hyperplasia. A review of the safety profile in older patients. The objective of this paper is to review the safety of doxazosin in older patients (>/=65 y) with benign prostatic hyperplasia (BPH) as reported in seven international clinical trials. Data from seven double-blind, placebo-controlled, phase III trials, in both normotensive and hypertensive patients with BPH were collated and analysed. Data on doxazosin were available for 341 men 65 y (...) and over. Even though older patients can be at particular risk of adverse drug reactions, there was no apparent evidence of poor tolerability with doxazosin in older patients with BPH. The percentages of younger normotensive BPH patients (<65 y) experiencing at least one adverse event were 47 and 44% for doxazosin and placebo groups, respectively; for older normotensive BPH patients (>/=65 y) the corresponding values were 42 and 38%. For the younger hypertensive BPH patients the incidence rates

1997 Prostate cancer and prostatic diseases Controlled trial quality: uncertain

20. Re: Comparison of the Efficacy of Isosorbide Mononitrate and Doxazosin in the Treatment of Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: A Randomized Clinical Trial. (Abstract)

Re: Comparison of the Efficacy of Isosorbide Mononitrate and Doxazosin in the Treatment of Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: A Randomized Clinical Trial. 26582690 2016 03 14 2018 12 02 1527-3792 194 6 2015 Dec The Journal of urology J. Urol. Re: Comparison of the Efficacy of Isosorbide Mononitrate and Doxazosin in the Treatment of Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: A Randomized Clinical Trial. 1702 10.1016/j.juro.2015.09.040 S0022-5347(15 (...) )04773-4 Kaplan Steven A SA eng Journal Article Comment 2015 09 21 United States J Urol 0376374 0022-5347 IA7306519N Isosorbide Dinitrate NW1291F1W8 Doxazosin AIM IM Urol Int. 2014;93(1):17-21 24643055 Doxazosin therapeutic use Humans Isosorbide Dinitrate analogs & derivatives Lower Urinary Tract Symptoms drug therapy Male Prostatic Hyperplasia drug therapy 2015 11 20 6 0 2015 11 20 6 0 2016 3 15 6 0 ppublish 26582690 S0022-5347(15)04773-4 10.1016/j.juro.2015.09.040

2016 The Journal of urology Controlled trial quality: uncertain